Incyte

Showing 11 posts of 26 posts found.

eli_lilly

Lilly’s RA drug baricitinib meets Phase III goals

March 31, 2016
Research and Development Eli Lilly, Incyte, rheumatoid arthritis

Eli Lilly and Incyte have announced the publication of detailed Phase III trial results from a study of their biologic …

incyte

Incyte to stop Jakafi pancreatic, colorectal cancer drug trials

February 11, 2016
Research and Development Incyte, Jakafi, Jakavi, Novartis, Pancreatic cancer, colorectal cancer

Incyte said today that it is terminating its JANUS clinical trial programme testing blood cancer drug Jakafi in solid tumours …

eli_lilly_logo

Lilly awaits FDA review of new arthritis treatment

January 20, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Eli Lilly, FDA, Incyte, NDA, baricitinib, lilly, new drug application, rheumatoid arthritis

Eli Lilly has submitted a new drug application (NDA) to the FDA for baricitinib as a treatment for moderate-to-severe rheumatoid …

a

AstraZeneca and MedImmune in oncology research deals

January 12, 2016
Manufacturing and Production, Research and Development AstraZeneca, Incyte, MedImmune, Moderna Therapeutics

AstraZeneca and its biologics arm MedImmune are launching new agreements with partner companies, to develop new targets for cancer, and …

MSD logo

Merck and Incyte to initiate Keytruda, epacadostat combo trial

October 15, 2015
Research and Development Incyte, Merck, R&D, melanoma, phase III, skin cancer

Merck and biopharma firm Incyte are to expand their clinical collaboration to include a Phase III study evaluating the combination …

Medimmune image

MedImmune signs Incyte oncology deal

May 15, 2014
Research and Development, Sales and Marketing AstraZeneca, Cancer, Incyte, MedImmune, oncology

MedImmune, the global biologics R&D arm of AstraZeneca, is to put one of its oncology immunotherapies into development in combination …

Incyte names former Novartis president as its chief executive

January 14, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Incyte, Novartis, hoppenot

Biopharma firm Incyte has announced that the former president of Novartis Oncology has been named as its president and chief …

Novartis’ myelofibrosis treatment approved in Europe

August 28, 2012
Sales and Marketing Incyte, Jakavi, Novartis, Orphan Drugs, myelofibrosis

Novartis’ Jakavi, a new treatment for patients with myelofibrosis has been approved in Europe. The drug was co-developed with Incyte, …

Novartis plans Q2 filing for blood cancer drug

March 17, 2011
Sales and Marketing COMFORT-II trial, INC424, Incyte, JAK, Janus kinase inhibitor, Novartis, blood cancer, cancer drug, myelofibrosis, ruxolitinib

Novartis will file ruxolitinib for worldwide regulatory approval in the second quarter after the cancer drug met its primary endpoint …

Incyte’s Novartis cancer drug deal could be worth $1bn

December 1, 2009
Research and Development Incyte, Novartis

Novartis has paid Incyte Corporation $150 million up front for the rights to two oral investigational hematology-oncology therapies.The first is …

The Gateway to Local Adoption Series

Latest content